Onset Therapeutics Announces FDA Submission for Novel Product for Topical Treatment of Genital Warts

CUMBERLAND, R.I.--(BUSINESS WIRE)--Onset Therapeutics, a specialty pharmaceutical company that focuses on the development and commercialization of innovative treatments for skin and skin related disorders, announced that it has submitted an application to the Food and Drug Administration (FDA) requesting approval for a product for the topical treatment of external genital warts. The Company has chosen not to disclose the active ingredient at this time.